Antibodies

21 Jan 2020 Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody
21 Jan 2020 European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
16 Jan 2020 PlantForm advances HIV antibody research in collaboration with scientists funded by U.S. National Institutes of Health
15 Jan 2020 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
15 Jan 2020 New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
14 Jan 2020 Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 Trial
13 Jan 2020 Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
13 Jan 2020 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
13 Jan 2020 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
13 Jan 2020 Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)
13 Jan 2020 Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
09 Jan 2020 Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients
09 Jan 2020 Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors
09 Jan 2020 Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
09 Jan 2020 Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers
09 Jan 2020 ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
09 Jan 2020 Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers
09 Jan 2020 Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40
09 Jan 2020 Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201
09 Jan 2020 Agenus Commences Phase 1 trial with AGEN1223
09 Jan 2020 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy
07 Jan 2020 Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
07 Jan 2020 Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
06 Jan 2020 BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
03 Jan 2020 I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top